Document is current
Any future updates will be listed below
-
Authors
Bojti, Istvan
Bojti, Felicitas
Hartikainen, Tau
Breibart, Philipp
Löffelhardt, Nikolaus
Valina, Christian
Franke, Kilian
Kaier, Klaus
Wolf, Dennis
Westermann, Dirk
Olivier, Christoph B.
-
Funding
Funding for this research was provided by:
Universitäts-Herzzentrum Freiburg - Bad Krozingen GmbH
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 25 June 2025
First Online: 2 August 2025
Declarations
:
: The protocol and amendments were approved by the local ethics committee, privacy and security offices, and institutional review board (Ethik-Kommission Albert-Ludwigs-Universität Freiburg, 21-1667). The need for consent to participate was waived by the institutional review board. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Not applicable.
: IB: speakers fee from Novartis, FB: none, TH: Travel Grants from Boston Scientific and Novartis, NL: speakers fee from BMS and Daiichi Sankyo, PB: consultant and speakers fee from AstraZeneca and Boehringer Ingelheim, DW: Honorary from Abiomed, Astra Zeneca, Bayer, Böhringer Ingelheim, Medtronic, Novartis, CV: none, DeW: research support from European Research Council, Deutsche Forschungsgemeinschaft, Else Kröner-Fresenius Stiftung. Honoraria: Novo Nordisc, Bayer, Novartis, UCB, Böhringer Ingelheim, CBO: research support from Haemonetics, Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, Else Kröner-Fresenius Stiftung Faculty of Medicine - Freiburg University; honoraria: Bayer Vital GmbH, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ferrer, Johnson & Johnson.
